Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
CL — frequently asked questions
Is Colgate-Palmolive Company overvalued?
In our latest published analysis dated 2026-09-27, CL screens modestly overvalued. The price recorded at analysis is 86,1 USD versus our fair value of 74,0 USD; the high endpoint is presented separately as potential value of 102 USD. That implies roughly 14.0% downside to fair value at that date.
Our latest published report, analyzed 2026-09-27, gives CL a fair value of 74,0 USD and a potential value of 102 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Colgate-Palmolive Company's archetype; it is a dated research output, not a live price.
Should I buy CL now?
Our latest published rating for CL, analyzed 2026-09-27, is Reduce. Colgate-Palmolive Company screens modestly overvalued at the analysis-date price of 86,1 USD versus fair value of 74,0 USD; potential value is 102 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for CL?
The dedicated bear-case section in our report analyzed 2026-09-27 documents Colgate-Palmolive Company's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is CL's rating?
Our latest published rating for CL, analyzed 2026-09-27, is Reduce, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 74,0 USD, the potential value of 102 USD, and the price recorded at analysis (86,1 USD).
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.
§1 Resumen ejecutivoEN
Respuesta en 30 segundosReduce
Precio frente a valor
Precio
$86.06
Valor razonable
$74.00
Valor potencial
$101.51
A fecha de
2026-09-25
Por qué puede funcionar
Accelerating global adoption and veterinarian recommendations for Hill's Pet Nutrition ($4.61B revenue in FY2025), combined with premium oral care tiering across emerging markets in Latin America and Asia, drives sustained 4-5% organic revenue growth, lifts gross margins beyond 62.0%, and normalizes operating margins above 20.5% toward our Potential value of $101.51.
Qué cambiaría nuestra opinión
North American shipment volumes trail consumption by more than 2 percentage points for two consecutive quarters, coupled with Walmart revenue share falling below 9.0%,.
We assign a Reduce rating to Colgate-Palmolive Company, as the stock price of $86.06 on September 25, 2026 sits 16.3% above our fundamental Fair value of $74.00,.3
Our Reduce rating indicates that investors should trim holdings or avoid allocating fresh capital to Colgate-Palmolive at current valuation levels. While the company is an exceptional defensive business with dependable dividend distributions, the market price has outrun fundamental cash-generation power. Investors face an unfavorable risk-reward profile where prospective returns fail to compensate for slowing category volume growth and margin headwinds.4
On September 25, 2026, the stock closed at $86.06. This price trades at a 16.3% premium to our Fair value midpoint of $74.00, representing 14.01% downside. Our valuation range indicates a of $101.51 under favorable long-term execution. However, achieving Potential value requires sustained expansion beyond 62% and accelerated volume growth in emerging markets,. At $86.06, the shares already price in aggressive operational recovery and leave little .
The primary risk that would accelerate downside is permanent working capital reduction by key mass retailers like Walmart, which represents 11.0% of net sales. In the second quarter of 2026, North American shipments fell 3% even as consumption grew 1%, because retail partners actively managed to leaner inventory baselines,. If retailers permanently cut inventory and expand private-label shelf space, shipment volumes will lag consumer demand, forcing Colgate to maintain double-digit increases in advertising spend to defend market share,. That cost pressure would cap operating margins near 17.5% and cause free cash flow to fall short of expectations.4,7,8
The primary driver that could support the stock toward our Potential value of $101.51 is continued science-backed premiumization in Hill's Pet Nutrition alongside international oral care expansion,. Hill's delivered $4.61 billion in revenue in 2025 and generates pricing power through veterinarian endorsements,. If premium pet food and specialized dental therapies accelerate consolidated organic sales growth to 4-5% while raw material costs remain benign, gross margins can sustain above 61.5%,. Operating leverage would then lift operating margins above 20.5% and push earnings per share toward $4.75 by 2030, raising intrinsic value per share.4,8
Global Oral Care Market Leadership
Colgate holds an entrenched global market position in toothpaste and manual toothbrushes, generating $15.77B in Oral, Personal and Home Care revenue in 2025.8
High-Margin Pet Nutrition Engine
Hill's Pet Nutrition generated $4.61B in 2025 sales and leverages veterinary endorsements to command premium pricing power and strong cash generation,.4,8
Dependable Dividend Aristocrat Cash Returns
Colgate maintains an unbroken multi-decade record of annual dividend increases supported by $3.63B in free cash flow and a modest 2.77% capex-to-revenue intensity,.6,7
Recomendación de la casa
We rate Colgate-Palmolive Reduce because the stock trades at $86.06, a 16.3% premium to our Fair value of $74.00, reflecting unrealistic margin and volume expectations amidst retailer inventory compression,,.3,4
Descripción general de la empresa
COLGATE-PALMOLIVE COMPANY operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition. COLGATE-PALMOLIVE COMPANY is a leader in Oral Care with global leadership in the toothpaste and manual toothbrush categories according to market share data.
§2 Caso bajistaEN
Under an integrated stress scenario where normalized cycle cost of equity reaches 8.5562%, retailers permanently depress working capital holding baselines, and advertising reinvestment remains elevated in double digits, Colgate's valuation compresses toward the lower bound of $50.65. At the share price of $86.06, trading at a forward P/E of 20.96x, the stock carries a 16.30% premium over Fair value of $74.00, leaving minimal valuation cushion against structural retail pushback or macro cost shocks.
Mass retailers permanently manage to reduced inventory holding baselines
Private-label substitution accelerates in essential mass categories
Elevated advertising expenditures fail to prevent volume slippage in untracked channels
Cost of capital normalizes toward historical sector baseline levels
In the bear outcome, persistent retailer inventory minimization combines with private-label substitution to compress shipment volumes, while necessary advertising spending restrains operating margin recovery. A normalization in the cost of capital further contracts valuation multiples. This downside path would be confirmed by consecutive quarters of shipment declines relative to consumption and gross margin deterioration.
The valuation's moderate cost of equity of 7.20% relies on an unsustainably low raw beta of 0.3352. If the discount rate normalizes toward the cycle cost of equity of 8.5562% (+200 bps shock), DDM fair value falls by -30.1% and discounted earnings fair value contracts by -32.2%, driving a -30.5% valuation contraction.1
FV impact
-25.5%
Señales de alerta temprana a vigilar
Los cinco acontecimientos que debilitarían nuestra tesis de inversión.
01
North American Shipment Growth Relative to Consumption
Persistent divergence indicates retailers are permanently compressing shelf inventory baselines or Colgate is losing channel market share,.
Actual:Shipments down 3% versus consumption up 1% (Q2 2026)
Alerta siVolume shipments lagging measured retail consumption by more than two percentage points across two consecutive quarters
Colgate-Palmolive possesses a wide economic moat rooted in dominant global oral care market share, entrenched consumer mindshare, and unmatched professional dentist advocacy. The core Oral, Personal and Home Care segment delivered $15,769M in FY2025 revenue, representing 77.37% of consolidated net sales of $20,382M. This foundation is reinforced by Hill's Pet Nutrition ($4,613M in FY2025), which operates a prescription and therapeutic nutrition model driven by clinical veterinary endorsements. Together, these franchises generate consistent, inelastic consumer demand across economic cycles.
Colgate's competitive advantage is reflected in exceptional return metrics, posting a return on invested capital of 38.62% that substantially surpasses its computed moderate cost of equity of 7.20% and computed WACC of 6.90%. The company's pricing power is demonstrated by gross margins reaching 60.11% in FY2025 ($12,251M gross profit on $20,382M revenue) and expanding to 61.48% in Q2 2026 ($3,296M gross profit on $5,361M revenue,). These margins meaningfully exceed consumer defensive peers including Procter & Gamble (50.87%), Kenvue (58.44%), and Archer-Daniels-Midland (6.87%,), confirming structural profitability advantages.
The durability of Colgate's moat is protected by extensive international distribution across more than 200 countries, limiting customer concentration risk. While Walmart Inc represents Colgate's largest retail customer at 11.0% of FY2025 net sales, 89% of revenue is broadly diversified across international supermarkets, independent grocers, pharmacies, and veterinary clinics. Sustained maintenance capital expenditures of $564M in FY2025 (2.77% of revenue) ensure modern supply chain infrastructure and localized manufacturing scale that cannot be easily replicated by regional competitors or private-label manufacturers.
Beneficio económico
Colgate's ROIC of 38.62% versus its computed WACC of 6.90% and moderate cost of equity of 7.20% yields an economic profit spread of 31.72 percentage points. This capital return profile reflects robust structural pricing power, as demonstrated by FY2025 consolidated gross margin of 60.11% ($12,251M gross profit on $20,382M revenue,) and Q2 2026 gross margin expansion to 61.48% ($3,296M gross profit on $5,361M revenue,). Even against a normalized cycle cost of equity of 8.5562%, Colgate maintains a 30.06 percentage point economic spread.1,5
9/ 10
Wide
Sources of advantage
01Global Distribution Network and Shelf Space Dominance — Colgate commands premier shelf space across global grocery, pharmacy, and mass merchant channels in over 200 countries, with single largest customer Walmart Inc accounting for 11.0% of FY2025 net sales and 89% distributed across independent and international channels.Wide
02Brand Equity and Professional Dentist Recommendation Intangibles — Colgate's flagship oral care franchise generated $15,769M in FY2025 revenue, supported by decades of dentist endorsements and consumer brand loyalty that enabled gross margins of 60.11% in FY2025 and 61.48% in Q2 2026, significantly exceeding peer gross margins (PG at 50.87%, KVUE at 58.44%, ADM at 6.87%,).Wide
Amenazas conocidas al foso
Amenaza
Severidad
Cronograma
Mitigación
Retailer Channel Margin Squeeze and Private-Label Substitution
medium
12-24 months
Continuous product premiumization, clinical efficacy tiering, and joint business planning with top retail partners like Walmart (11.0% of FY2025 revenue).8
The highlighted cell is Fair value when every assumption sits at its base level ($74.00). Each row and column shows what Fair value becomes when one assumption moves.
In the base outcome, yielding $74.00 with an estimated probability of 60.0% and an expected return of -14.0%, Colgate-Palmolive delivers steady organic growth across its core franchises. Mass merchant channel inventory stabilizes, and gross profit gains are balanced by necessary advertising reinvestment to maintain defensive market share. However, because $86.06 trades above Fair value of $74.00, the expected return profile remains negative at -14.0%, validating a Reduce recommendation.
Accelerated premiumization in Pet Nutrition and international oral care driving sustained above-trend revenue growth
Gross margin expansion supported by supply-chain productivity savings and benign commodity input costs
§7 Árbol de decisión de resultadosEN
Superado
Upgrade the rating; Pause trimming actions; verify whether volume improvements in untracked channels and gross margin gains persist into subsequent quarters before considering re-allocating capital
An upside inflection where shipment volumes catch up to underlying consumption and untracked channel market share stabilizes would confirm that operating margin targets can be achieved ahead of schedule, reducing downside risk relative to $74.00
En línea
Maintain Reduce; Proceed with scheduled portfolio reduction toward an underweight allocation, rebalancing capital into alternatives with greater margin of safety
Disparador: Organic sales growth meets consensus projections with gross margins remaining stable and operating margins matching target recovery path
In-line performance confirms steady defensive cash conversion but leaves the valuation stretched, as $86.06 continues to trade at a substantial premium to $74.00
Fallo
Downgrade the rating; Accelerate liquidation of remaining positions, setting checkpoints to monitor shelf-space losses and gross margin erosion across major retail accounts
Disparador: Organic sales contraction driven by retailer inventory minimization and private-label substitution, combined with operating margin compression from elevated commercial reinvestment
A failure in organic volume growth combined with gross margin erosion would disconfirm the pricing power thesis, indicating that retail customer pushback and advertising inflation are permanently impairing earnings power
ActualShipments trailed consumption in the recent quarter due to retailer inventory reductions
Por qué importa
When shipments diverge negatively from consumption, it reveals whether retailers are permanently managing to leaner inventory baselines or whether national brand shelf space is being ceded to private-label alternatives
02
Métrica:
Gross Margin Durability Against Commodity Pressures
ActualExpanded in recent quarters supported by pricing and temporary tariff benefits
Colgate's cash generation exhibits high accounting fidelity and defensive consistency. FY2025 operating cash flow of $4,198M substantially exceeded GAAP net income of $2,132M,, delivering an operating cash conversion ratio of 1.97x net income. Free cash flow of $3,634M represented 17.83% of consolidated revenue ($20,382M). In Q2 2026, free cash flow grew 18%, driven by gross margin expansion to 61.48% ($3,296M gross profit on $5,361M revenue,). Modest annual capex requirements ($564M in FY2025, with maintenance capex estimated at 85% or $479.4M) ensure that over 85% of operating cash flow converts directly into discretionary ($2,282.6M in normalized owner earnings).
Colgate's ROIC trajectory reflects enduring brand pricing power and an asset-light manufacturing model. While treasury share repurchases reduce stated book equity, underlying operational capital returns remain structurally insulated from cyclical compression.
Colgate's latest ROIC of 38.62% vastly outstrips its computed WACC of 6.90% and moderate cost of equity of 7.20%, generating a spread of over 31 percentage points.
FY2025 operating cash flow of $4,198M and capex of $564M delivered $3,634M in FCF, supporting $1.4B returned to shareholders in Q2 2026 alone.
Ingresos más recientes20,4 mil M US$CAGR de ingresos +3,3 %
Margen operativo16,2 %10 periodos fiscales
Flujo de caja libre más reciente3634 M US$FY2025
Deuda neta6444 M US$FY2025
Desglose de la cuenta de resultadosCómo la escala del negocio se convierte en beneficio declarado.
StockMarketAgent.AI
Ingresos20,4 mil M US$Coste de ventas−8131 M US$Beneficio bruto12,3 mil M US$Gastos operativos−8945 M US$Beneficio operativo3306 M US$Partidas no operativas e impuestos−1174 M US$Beneficio neto2132 M US$
Datos del historial financiero
Ingresos
20.382.000.000 US$
Coste de ventas
8.131.000.000 US$
Beneficio bruto
12.251.000.000 US$
Gastos operativos
8.945.000.000 US$
Beneficio operativo
3.306.000.000 US$
Partidas no operativas e impuestos
-1.174.000.000 US$
Beneficio neto
2.132.000.000 US$
Resumen del balanceCómo se mantienen y financian los activos declarados en el período seleccionado.
StockMarketAgent.AI
Composición de activosFinanciado por
Activos totales16,3 mil M US$Efectivo1288 M US$Activos corrientes5709 M US$Pasivos totales16 mil M US$Pasivos corrientes6853 M US$Patrimonio neto365 M US$
Datos del desglose del balance
Activos totales
16.330.000.000 US$
Efectivo
1.288.000.000 US$
Activos corrientes
5.709.000.000 US$
Pasivos totales
15.965.000.000 US$
Pasivos corrientes
6.853.000.000 US$
Patrimonio neto
365.000.000 US$
Puente de flujo de cajaCómo el flujo de caja operativo se convirtió en flujo de caja libre en FY2025.
StockMarketAgent.AI
Conciliación del flujo operativo
Beneficio neto2132 M US$Depreciación y amortización+630 M US$Compensación basada en acciones+155 M US$Otros ajustes operativos+1281 M US$Flujo de caja operativo4198 M US$
Conciliación del efectivo inicial al final
Efectivo inicial1096 M US$Flujo de caja operativo+4198 M US$Flujo de inversión−817 M US$Flujo de financiación−3256 M US$Efecto del tipo de cambio+67 M US$Efectivo final1288 M US$
4198 M US$ − 564 M US$Flujo de caja libre 3634 M US$
Datos del puente de flujo de caja
Beneficio neto
2.132.000.000 US$
Entrada operativa
4.198.000.000 US$
Depreciación y amortización
630.000.000 US$
Compensación basada en acciones
155.000.000 US$
Otros ajustes operativos
1.281.000.000 US$
Flujo de caja operativo
4.198.000.000 US$
Efectivo disponible
5.361.000.000 US$
Efectivo inicial
1.096.000.000 US$
Efecto del tipo de cambio
67.000.000 US$
Salida de inversión
817.000.000 US$
Capex
564.000.000 US$
Otras actividades de inversión
253.000.000 US$
Salida de financiación
3.256.000.000 US$
Efectivo final
1.288.000.000 US$
Flujo de inversión
-817.000.000 US$
Flujo de financiación
-3.256.000.000 US$
Ingresos por segmento operativoProporción de los ingresos totales de 2025-12-31.
20,4 mil M US$Ingresos totales
Ingresos por segmento operativoProporción
Oral Personal And Home Care15,8 mil M US$77,4 %+1 % interanual
Pet Nutrition4613 M US$22,6 %+2,9 % interanual
Fuente: SEC EDGAR · Presentado 2026-02-23 · SEC EDGAR
Datos de composición de ingresos: Ingresos por segmento operativo
Ingresos por segmento operativo
Ingresos
Proporción
interanual
Oral Personal And Home Care
15,8 mil M US$
77,4 %
1 %
Pet Nutrition
4613 M US$
22,6 %
2,9 %
Ingresos y beneficiosCómo la escala del negocio se convierte en beneficio declarado.
Efectivo y deudaLiquidez disponible frente al endeudamiento total.
Generación de efectivoFlujo de caja operativo frente al flujo de caja libre.
RentabilidadEvolución de los márgenes bruto, operativo y neto.
Datos financieros puntuales utilizados en el análisis del 2026-09-27.
Datos del historial financiero
Período
Ingresos
EBITDA
Beneficio neto
Flujo de caja operativo
Flujo de caja libre
Capex
Depreciación y amortización
Compensación basada en acciones
Recompras de acciones
Dividendos pagados
Emisión neta de deuda
Flujo de inversión
Flujo de financiación
Efectivo inicial
Efectivo final
Efectivo e inversiones
Deuda total
Margen operativo
ROIC
WACC
Diferencial ROIC−WACC
2016-12-31
15,2 mil M US$
4330 M US$
2441 M US$
3141 M US$
2548 M US$
593 M US$
443 M US$
123 M US$
1335 M US$
1508 M US$
—
-499 M US$
-2233 M US$
—
1315 M US$
1386 M US$
6520 M US$
26,0 %
—
5,1 %
—
2017-12-31
15,5 mil M US$
4115 M US$
2024 M US$
3054 M US$
2501 M US$
553 M US$
475 M US$
127 M US$
1399 M US$
1529 M US$
—
-471 M US$
-2450 M US$
1315 M US$
1535 M US$
1549 M US$
6566 M US$
24,0 %
—
5,3 %
—
2018-12-31
15,5 mil M US$
4168 M US$
2400 M US$
3056 M US$
2620 M US$
436 M US$
511 M US$
109 M US$
1238 M US$
1591 M US$
—
-1170 M US$
-2679 M US$
1535 M US$
726 M US$
736 M US$
6354 M US$
23,8 %
—
5,4 %
—
2019-12-31
15,7 mil M US$
4012 M US$
2367 M US$
3133 M US$
2798 M US$
335 M US$
519 M US$
100 M US$
1202 M US$
1614 M US$
—
-2099 M US$
-870 M US$
726 M US$
883 M US$
906 M US$
15,2 mil M US$
22,6 %
—
4,3 %
—
2020-12-31
16,5 mil M US$
4346 M US$
2695 M US$
3719 M US$
3310 M US$
409 M US$
539 M US$
107 M US$
1476 M US$
1654 M US$
—
-779 M US$
-2919 M US$
883 M US$
888 M US$
925 M US$
7738 M US$
23,6 %
—
3,1 %
—
2021-12-31
17,4 mil M US$
3760 M US$
2166 M US$
3325 M US$
2758 M US$
567 M US$
556 M US$
135 M US$
1320 M US$
1679 M US$
—
-592 M US$
-2774 M US$
888 M US$
832 M US$
866 M US$
7433 M US$
19,1 %
—
3,8 %
—
2022-12-31
18 mil M US$
3372 M US$
1785 M US$
2556 M US$
1860 M US$
696 M US$
545 M US$
125 M US$
1308 M US$
1691 M US$
1647 M US$
-1601 M US$
-952 M US$
832 M US$
775 M US$
950 M US$
9271 M US$
16,1 %
—
5,8 %
—
2023-12-31
19,5 mil M US$
4246 M US$
2300 M US$
3745 M US$
3040 M US$
705 M US$
567 M US$
122 M US$
1128 M US$
1749 M US$
-314 M US$
-742 M US$
-2793 M US$
775 M US$
966 M US$
1145 M US$
9064 M US$
20,5 %
—
5,7 %
—
2024-12-31
20,1 mil M US$
4853 M US$
2889 M US$
4107 M US$
3546 M US$
561 M US$
605 M US$
135 M US$
1739 M US$
1789 M US$
-408 M US$
-534 M US$
-3389 M US$
966 M US$
1096 M US$
1256 M US$
7005 M US$
21,2 %
—
6,4 %
—
2025-12-31
20,4 mil M US$
3956 M US$
2132 M US$
4198 M US$
3634 M US$
564 M US$
630 M US$
155 M US$
1210 M US$
1823 M US$
-456 M US$
-817 M US$
-3256 M US$
1096 M US$
1288 M US$
1395 M US$
7839 M US$
16,2 %
—
5,6 %
—
§9 Comparación de valoración con pares
Valor razonableReport-date price
Colgate-Palmolive CompanyCL
Precio / valor razonable
Valor razonable74 US$Report-date price86,06 US$
Fecha de evaluación
Ventaja competitivaWide
Cuadro de mando de inversión63 / 100
The Procter & Gamble CompanyPG
Precio / valor razonable
Valor razonable126,47 US$Report-date price145,58 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión56 / 100
Archer-Daniels-Midland CompanyADM
Precio / valor razonable
Valor razonable71,52 US$Report-date price80,45 US$
Colgate-Palmolive Company (CL) trades at 21.0x forward earnings against a peer median of 17.1x. Its EV/EBITDA of 15.1x compares with a peer median of 15.3x. The comparison uses 4 peers: The Procter & Gamble Company, Archer-Daniels-Midland Company, Kenvue Inc. and The Estee Lauder Companies Inc., as of 2026-09-27.
§10 Industria y cicloEN
Fase del ciclo
Expansion
Household and personal products industry capex-to-revenue stands at 1.1% (0.011) and industry capex-to-depreciation stands at 1.07 as of September 2026. Colgate-Palmolive invested $564M in capex in FY2025 on $20,382M revenue (2.77% capex-to-revenue), while industry operating margin benchmark is 18.8% and gross margin is 51.0%.7
Ciclo alcista
In an industry upcycle, consumer spending in oral health and pet nutrition accelerates toward premiumized clinical formulations, emerging market household incomes expand per-capita toothpaste usage, and mass retailers expand shelf space and inventory allocations, allowing consumer defensive leaders to deliver 4-6% organic revenue growth and expand gross margins beyond 62%.
Ciclo bajista
In an industry downcycle, consumer spending power weakens, prompting down-trading to private-label alternatives at mass retailers like Walmart (11.0% customer revenue share), while mass retailers aggressively destock inventories to minimize working capital. Pricing power dissipates after upfront inflation realization, and intense promotional discounting across peers compresses operating margins below historical averages.
Tendencias seculares
Tendencia
Impacto
Nota
Veterinary-Backed Premium Pet Nutrition Demand
positive
Pet humanization and increasing clinical veterinary care drive sustained demand for Hill's Pet Nutrition science-backed formulations, enabling volume and pricing growth above standard consumer staple rates.
Emerging Market Oral Hygiene Adoption and Premiumization
positive
Rising disposable incomes in Latin America, Asia Pacific, and Africa expand per-capita toothpaste and toothbrush consumption, while driving mix shift into higher-margin therapeutic oral care segments.
Posicionamiento
Colgate holds an advantaged position within consumer defensive staples due to its 77.37% concentration in essential Oral, Personal and Home Care ($15,769M in FY2025) and high-margin Pet Nutrition franchise ($4,613M in FY2025). Its gross margin of 60.11% in FY2025 and 61.48% in Q2 2026 outpaces peer Procter & Gamble at 50.87% and Kenvue at 58.44%, providing a superior gross profit buffer against cyclical downturns.7,8
§11 Gestión de posiciónEN
Tamaño de posición
0-1%
Colgate-Palmolive trades at $86.06, representing a 16.30% premium over synthesized Fair value of $74.00 and implying an upside of -14.01%. At a forward P/E of 20.96x, the stock commands an unwarranted premium over peers such as Procter & Gamble at 19.76x and Kenvue at 14.36x,. Consequently, an underweight portfolio allocation of 0-1% is recommended, advising investors to trim holdings.2,3
Riesgo
Risk management focuses on capital preservation given negative expected returns (-14.01%). Investors should rebalance out of CL into defensive staples offering favorable risk-reward profiles. Portfolio exposure should be capped at 1% of total equity assets, using any price strength above $88.00 as an opportunity to complete orderly divestment.
Tramos de entrada
Nivel
Acción
Por qué
$74.00 (Synthesized Fair Value Midpoint)
Consider initial nibble or neutral rebalancing only upon complete valuation reset
Realigns share price with fundamental fair value, eliminating the current 16.30% market valuation premium.
Colgate trades at a forward P/E of 20.96x, commanding a rich premium over peer leader Procter & Gamble at 19.76x and Kenvue at 14.36x,. With the stock trading at an implied 16.3% premium to our Fair value of $74.00, value investors should avoid initiating positions until a meaningful margin of safety emerges.2,3
Dividend & Income Investor
Hold
Colgate is a premier Dividend Aristocrat with 61 consecutive years of dividend increases, backed by $3.63B in free cash flow and a healthy dividend payout. Existing income-focused shareholders can hold for steady distributions, but should avoid reinvesting dividends at current valuations above $86.3,6
Total Return & Tactical Investor
Avoid
With upside capped and negative prospective returns of -14.01% to Fair value, tactical capital faces adverse asymmetry. Persistent retail destocking and subdued category growth in North America limit near-term catalysts for multiple expansion,.4
§14 Recomendación finalEN
Acción
Reducir
We recommend reducing exposure to Colgate-Palmolive Company. At $86.06 on September 25, 2026, the stock trades at a 16.3% premium over our Fair value of $74.00,. While Colgate is an exemplary consumer defensive business with an enviable 38.62% return on invested capital, current pricing already reflects an aggressive operational recovery, leaving zero margin of safety against retail inventory compression.1,3,4
Investors should capitalize on current trading multiples (20.96x forward P/E) to lock in gains and redeploy into consumer defensive peers offering wider margins of safety or higher cash yields. Maintain trailing stop-losses and monitor retail shipment recovery in upcoming quarters.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Colgate trades at a forward P/E of 20.96x while peer leader Procter & Gamble trades at 19.76x and Kenvue trades at 14.36x. With management cautioning that category demand is unlikely to inflect positively in H2 2026, multiple compression from 19.5x to peer median of 15.6x (-20%) reduces forward earnings fair value by -20.0%.2,3,4
FV impact
-1.5%
Terminal multiple 20% lower
Trigger
Within 24 months
Structural Reinvestment and Input Cost Pressure Caps Operating Margins
FY2025 operating margin was 16.22% ($3,306M on $20,382M revenue,). If normalized operating margins stall at 17.5%—3.0 percentage points below the 20.5% normalized target—due to mandatory double-digit advertising spending to combat untracked channel share loss, and fading FX tailwinds, normalized earnings power contracts by -18.5%.4,7
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 18 months
Category Stagnation and Private-Label Substitution Halves Long-Term Growth
Mass retailers minimizing inventory baselines, Walmart expanding private label offerings (11.0% revenue share), and mature category volume stagnation reduce terminal growth by 100 bps from 2.5% to 1.5%, cutting DDM fair value by -14.8% and discounted earnings by -13.2%.4,8
FV impact
-10.1%
Terminal growth 1 point lower
Trigger
Within 36 months
Signals exhaustion of pricing power against raw material cost inflation and retail customer resistance,.
Confirms that required double-digit advertising reinvestment and input cost pressures are permanently capping margin recovery below the 20.5% normalized target,.
Actual:16.22% (FY2025)
Alerta siOperating margin remaining at or below 17.50% in FY2026
05
Untracked Channel Oral Care Market Share
Signals competitive encroachment by diversified peers and e-commerce platform disruption outpacing double-digit marketing investments,.
Actual:Market share contraction acknowledged in Q2 2026
Alerta siGlobal toothpaste volume market share falling by more than 150 bps year-over-year
Proprietary Science-Based Formulations and Veterinary Network — Hill's Pet Nutrition generated $4,613M in FY2025 net sales leveraging a specialized veterinary recommendation model, clinical dietary formulations, and premium brand credentials.
Moderate
Market Share Slippage in Untracked and E-Commerce Channels
medium
6-18 months
Management committed double-digit increases in advertising spend and targeted digital marketing innovation in disrupted markets like China to reverse untracked channel volume loss.4
Agricultural Commodity and Resin Packaging Cost Inflation
low
12-36 months
Proactive revenue growth management pricing actions, Funding the Growth productivity programs, and forward raw material contracting.4
Terminal price-to-earnings valuation multiple expanding on premium brand positioning
In the bull outcome, projected at $101.51 with an estimated probability of 15.0% and an expected return of 18.0%, Colgate-Palmolive accelerates international oral care premiumization while Hill's Pet Nutrition expands veterinary market share globally. Gross margin gains outpace cost inflation, allowing operating margins to surpass historical peaks even after funding strong commercial marketing. This scenario would be disconfirmed if retail partners resist premium shelf allocation or if emerging market currency devaluations erode reported sales gains.
Gross margin stability reveals whether pricing power remains intact as raw material costs evolve and retail partners push back on list prices
03
Métrica:
Walmart Channel Concentration and Private Label Encroachment
ActualSingle largest customer accounts for over one-tenth of total consolidated sales
Por qué importa
Tracking customer concentration reveals whether mass retail partners are successfully expanding private-label penetration or extracting larger promotional allowances at the expense of national brand operating profit
04
Métrica:
Commercial Advertising Reinvestment Ratio
ActualAdvertising spend elevated at double-digit growth rates to protect untracked channel presence
Por qué importa
Persistent double-digit advertising increases demonstrate whether promotional spending is defensive maintenance to stem share loss or productive demand generation that creates operating leverage
05
Métrica:
Veterinary Pet Nutrition Volume Growth
ActualMaintains steady revenue growth backed by clinical veterinary recommendations
Por qué importa
Pet Nutrition provides the primary growth and premiumization driver outside oral care; deceleration here directly reduces consolidated top-line growth expectations
Colgate executes a disciplined, shareholder-friendly capital allocation strategy characteristic of a premier dividend aristocrat. In FY2025, the company generated $4,198M in operating cash flow and allocated just $564M to capital expenditures (2.77% of revenue), producing $3,634M in free cash flow. In Q2 2026, free cash flow expanded 18% year-over-year, enabling the return of $1.4B to shareholders via dividends and share repurchases. Total debt stands at $7,856,999,936 against a market capitalization of $68,604,690,000,, representing a manageable debt weight of 10.28% and pre-tax cost of debt of 5.72%.
Dividend safety and capital return durability remain uncompromised even during periods of volume stagnation.
Gross Margin Expansion Offset by Commercial Reinvestment
Q2 2026 gross margin reached 61.48% ($3,296M gross profit on $5,361M revenue; cost of revenue $2,065M), but operating income compressed in FY2025 to $3,306M (16.22% margin) as advertising spend stepped up by double digits.
Operating leverage is restrained as gross profit gains must be reinvested in advertising to defend untracked channel market share.
Valuation Disconnect Between Cash Return Models and Market Multiple
Current share price of $86.06 trades at forward P/E of 20.96x,, commanding a 16.30% premium over Fair value of $74.00 and well above cash return models like DDM ($51.65) and owner earnings ($55.84).
The market prices in full operating margin normalization toward 20.5% without discounting retail inventory and cost of capital risks.
Kenvue Inc.KVUE
Precio / valor razonable
Valor razonable18,17 US$Report-date price17,2 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión63 / 100
The Estee Lauder Companies Inc.EL
Precio / valor razonable
Valor razonable51,63 US$Report-date price91,97 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión48 / 100
Margen
CL
Colgate-Palmolive Company
$68.6B
21.0x
3.3x
15.1x
267.4%
—
PG
The Procter & Gamble Company
$339.9B
19.8x
3.9x
14.8x
30.3%
22.1%
ADM
Archer-Daniels-Midland Company
$39.1B
14.3x
0.5x
15.9x
7.6%
4.0%
KVUE
Kenvue Inc.
$34.2B
14.4x
2.2x
12.0x
15.6%
19.4%
EL
The Estee Lauder Companies Inc.
$34.2B
24.1x
2.3x
16.3x
4.7%
7.0%
Retail Channel Inventory Minimization and Private-Label Expansion
negative
Mass retailers continuously deploy automated inventory systems to lower stock baselines while aggressively expanding store-brand oral care lines at retail partners like Walmart (11.0% revenue share), capping national brand volume growth.
Cut terminal multiple assumption and accelerate portfolio divestment.
